Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BV-ICE for Relapsed or Refractory Hodgkin Lymphoma
NCT02227199Phase 2Completed
- Sponsor
- University of Washington
- Start
- Oct 2014
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of brentuximab vedotin in Hodgkin lymphoma (HL) (3 arms), sponsored by University of Washington. Primary endpoints: Maximum Tolerated Dose at 70 days and Complete Remission Rate. Started Oct 2014; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02227199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227199.